DPP4 and type 2 diabetes mellitus: According to research, GLP-1R agonists (GLP-1RAs) have a greater impact on hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), blood lipids, and body weight in patients with type 2 diabetes than DPP4 inhibitors [6].